Table 4. Logistic regression analysis of pretreatment factors relating to parametrial involvement.
| Pretreatment factor | Parametrial involvement | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| Odds ratio (95% CI) | p-value | Odds ratio (95% CI) | p-value | ||
| MRI-based tumor diameter (mm) | |||||
| <25 | 3/87 (3.4) | 1 | 1 | ||
| ≥25 | 15/28 (53.6) | 32.3 (8.21-127.2) | <0.001 | 9.9 (2.05-48.1) | <0.001 |
| MRI-based volume index (mm3) | |||||
| <5,000 | 1/74 (1.4) | 1 | 1 | ||
| ≥5,000 | 17/41 (41.5) | 51.7 (6.53-409.4) | <0.001 | 13.3 (1.41-125.0) | 0.024 |
| Serum tumor marker | |||||
| Negative* | 4/71 (5.6) | 1 | 1 | ||
| Positive† | 14/44 (31.8) | 7.8 (2.37-25.7) | <0.001 | 5.7 (1.29-25.1) | 0.022 |
Values are presented as number/total number (%).
CA-125, cancer antigen 125; CI, confidence interval; MRI, magnetic resonance imaging; SCC, squamous cell carcinoma.
*SCC-Ag <1.5 ng/mL and CA-125 <35 U/mL. †SCC-Ag ≥1.5 ng/mL or CA-125 ≥35 U/mL.